Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.2K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

250
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
250
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

512
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
512
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

161
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
161
Angina IV: Management01:26

Angina IV: Management

163
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
163
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.1K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global survey of genetic testing methods for familial hypercholesterolemia. A study and recommendations from the EAS FHSC registry.

European journal of preventive cardiology·2026
Same author

WHF Roadmap for Integrated Care in People Living with - or at Risk of - Cardiovascular Disease and Multiple Long-Term Conditions.

Global heart·2026
Same author

Brazilian Guideline on Dyslipidemias and Prevention of Atherosclerosis - 2025.

Arquivos brasileiros de cardiologia·2025
Same author

Guideline for Chronic Coronary Syndrome - 2025.

Arquivos brasileiros de cardiologia·2025
Same author

LDL-cholesterol lowering, the earlier the better: lessons from the real world.

European heart journal. Quality of care & clinical outcomes·2025
Same author

The Metabolic Vulnerability Index (MVX) in Subclinical Thyroid Disorders and Euthyroidism: A Cross-Sectional Exploratory Analysis from the ELSA-Brasil Study.

Metabolites·2025

Related Experiment Video

Updated: Dec 12, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.9K

The Role of Statins in Current Guidelines.

Fabiana Rached1, Raul D Santos2,3

  • 1Heart Institute-InCor, University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil.

Current Atherosclerosis Reports
|August 10, 2020
PubMed
Summary

Guidelines for preventing atherosclerotic cardiovascular disease (ASCVD) have evolved over 30 years, emphasizing intensive LDL-cholesterol (LDL-C) lowering. Statins remain the cornerstone of ASCVD prevention, despite new therapies.

Keywords:
AtherosclerosisCardiovascular diseaseCholesterolGuidelinesStatins

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.9K

Related Experiment Videos

Last Updated: Dec 12, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.9K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.9K

Area of Science:

  • Cardiology
  • Public Health

Background:

  • Low-density lipoprotein cholesterol (LDL-C) is causally linked to atherosclerotic cardiovascular disease (ASCVD).
  • Extensive evidence from experimental, epidemiological, genetic, and interventional studies supports this association.

Purpose of the Study:

  • To review the evolution of ASCVD prevention guidelines over the past three decades.
  • To demonstrate how knowledge from statin randomized controlled trials (RCTs) influenced these guidelines.

Main Methods:

  • Analysis of guideline evolution based on accumulating data from statin RCTs.
  • Review of recommendations for LDL-C lowering strategies in ASCVD prevention.

Main Results:

  • Guideline recommendations for LDL-C lowering have become progressively more intensive.
  • Recent guidelines universally recommend intensive LDL-C reduction for high-risk individuals.
  • Discrepancies exist in risk stratification, LDL-C targets, primary prevention, and initiation thresholds for non-statin therapies.

Conclusions:

  • Statins remain the primary therapy for ASCVD prevention due to their efficacy, safety, and cost-effectiveness.
  • Intensive LDL-C lowering with statins is crucial for evidence-based ASCVD prevention.
  • Non-statin therapies complement statins but do not replace them as the main strategy.